Jeil Pharma Holdings Inc (002620.KS)

KRW 7990.0

(-3.5%)

Market Cap (In KRW)

122.65 Billion

Revenue (In KRW)

794.71 Billion

Net Income (In KRW)

-16.24 Billion

Avg. Volume

42.01 Thousand

Currency
KRW
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
7200.0-12380.0
PE
-
EPS
-
Beta Value
1.162
ISIN
KR7002620003
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Seung-Soo Han
Employee Count
-
Website
https://www.jeilpharm.co.kr
Ipo Date
2000-01-04
Details
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea. The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products. It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine, rheumatology, respiratory, otolaryngological, heaptic, laxatives, and purgatives. The company exports its products to approximately 40 countries in the Association of Southeast Asian Nations, Central and South America, Africa, etc. Jeil Pharma Holdings Inc was founded in 1959 and is headquartered in Seoul, South Korea.